ClinicalTrials.gg
CompletedNCT06620172Updated Sep 22, 2026

CT-guided vs Fluoroscopy-guided Trigeminal Ganglion Radiofrequency Thermocoagulation for Idiopathic Trigeminal Neuralgia

An interventional study of CT-guided Radiofrequency Thermocoagulation (RFT) and Fluoroscopy-guided Radiofrequency Thermocoagulation (RFT) in Trigeminal Neuralgia and Trigeminal Neuralgia, Idiopathic, sponsored by Zagazig University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Zagazig University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The goal of this clinical trial is to compare the effectiveness and safety of CT-guided versus fluoroscopy-guided trigeminal ganglion radiofrequency thermocoagulation (TG-RFT) in treating idiopathic trigeminal neuralgia (TN) in adults aged 18 and older.

The main questions it aims to answer are:

  • Does CT-guided TG-RFT provide better pain relief compared to fluoroscopy-guided TG-RFT?
  • What are the differences in medication consumption between the two methods?
  • What are the procedure-related adverse events for both methods?

Investigators will compare CT-guided TG-RFT to fluoroscopy-guided TG-RFT to see if one method is superior in treating idiopathic TN.

Participants will:

  • Undergo either CT-guided or fluoroscopy-guided TG-RFT procedure
  • Be monitored post-procedure and followed up at 1, 3, and 6 months for pain relief, medication consumption, and adverse events.
Read the detailed description

This randomized controlled trial aims to compare the efficacy and safety of CT-guided versus fluoroscopy-guided trigeminal ganglion radiofrequency thermocoagulation (TG-RFT) in patients with idiopathic trigeminal neuralgia (TN). Idiopathic TN is characterized by severe, recurrent facial pain, and radiofrequency thermocoagulation is a common interventional treatment option.

Participants eligible for this study will be adults over 18 years old, diagnosed with idiopathic TN based on the International Headache Society criteria, experiencing pain for at least six months with a numeric rating scale (NRS) score greater than 6 despite medical treatment.

Exclusion criteria include vascular compression of the trigeminal nerve by MRI, secondary causes such as multiple sclerosis, trigeminal autonomic cephalalgias, dental or temporomandibular joint pathologies, previous interventional procedures or surgery for TN, coagulopathy, use of antiaggregants and anticoagulants, cardiac pacemaker, renal-hepatic insufficiency, psychiatric illness, malignancy, or infection at the injection site or systemic infection.

Participants will be randomly assigned to either the CT-guided or fluoroscopy-guided RFT group using a computer-generated randomization list. Both procedures will be performed under aseptic conditions with appropriate monitoring and anesthesia. The CT-guided RFT will use real-time CT imaging for needle placement and monitoring, while the fluoroscopy-guided RFT will use fluoroscopic imaging.

The primary outcome measure is pain relief, assessed at 1-, 3-, and 6-months post-procedure using the Numeric Rating Scale (NRS) and Visual Analog Scale (VAS). Secondary outcomes include changes in medication consumption assessed by the Medication Quantification Scale III (MQS III) and the recording of procedure-related adverse events.

This study aims to provide valuable insights into the comparative effectiveness and safety of CT-guided versus fluoroscopy-guided TG-RFT in managing idiopathic TN, potentially guiding future clinical practice.

02

Conditions studied

  • Trigeminal Neuralgia
  • Trigeminal Neuralgia, Idiopathic

Browse trials for

Keywords

  • CT-guided Radiofrequency Thermocoagulation
  • Fluoroscopy-guided Radiofrequency Thermocoagulation
  • Idiopathic Trigeminal Neuralgia
  • Pain Management
  • Interventional Pain Treatment
03

In context

Trigeminal Neuralgia

140 studies on the registry are indexed under Trigeminal Neuralgia; 44 are open to participants now.

This study's enrollment of 68 is above the median of 40 across 93 interventional studies indexed under Trigeminal Neuralgia.

Browse Trigeminal Neuralgia studies →

Lead sponsor

Zagazig University is the lead sponsor of 462 studies on the registry; 78 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • Idiopathic trigeminal neuralgia (TN) based on the International Headache Society criteria
  • Pain for at least six months and a NRS score greater than 6 despite medical treatment
  • Able to provide .
  • Agree to follow the study procedures and attend follow-up visits.

Exclusion criteria

Exclusion Criteria:

  • Vascular compression of the trigeminal nerve by MRI and MRI angiography and the presence of secondary causes such as multiple sclerosis
  • Trigeminal autonomic cephalalgias accompanied by autonomic symptoms
  • Dental or temporomandibular joint pathologies
  • Previous interventional procedures or surgery for TN
  • Coagulopathy or use of antiaggregants and anticoagulants
  • Cardiac pacemaker
  • Renal-hepatic insufficiency
  • Diagnosis of psychiatric illness
  • Injection site or systemic infection
  • Current participation in another clinical trial that could interfere with the outcomes of this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    CT-guided RFT

    Participants will undergo CT-guided trigeminal ganglion radiofrequency thermocoagulation (RFT) with real-time CT imaging for needle placement and monitoring.

    Procedure: CT-guided Radiofrequency Thermocoagulation (RFT)

  • Active comparator
    Fluoroscopy-guided RFT

    Participants will undergo fluoroscopy-guided trigeminal ganglion radiofrequency thermocoagulation (RFT) with fluoroscopic imaging for needle placement and monitoring.

    Procedure: Fluoroscopy-guided Radiofrequency Thermocoagulation (RFT)

Interventions

  • ProcedureCT-guided Radiofrequency Thermocoagulation (RFT)

    Participants in this group will undergo CT-guided trigeminal ganglion radiofrequency thermocoagulation (RFT). The procedure involves real-time CT imaging to guide the placement of the needle and monitor the process.

  • ProcedureFluoroscopy-guided Radiofrequency Thermocoagulation (RFT)

    Participants in this group will undergo fluoroscopy-guided trigeminal ganglion radiofrequency thermocoagulation (RFT). The procedure utilizes fluoroscopic imaging for needle placement and monitoring.

06

What researchers measure

Primary outcomes

  1. Pain Relief - Numeric Rating Scale (NRS)

    The primary outcome measure will be the level of pain relief, as assessed by the Numeric Rating Scale (NRS), a 0-10 scale where 0 represents "no pain" and 10 represents "worst possible pain.". Pain levels will be recorded at baseline (pre-procedure), immediately post-procedure, and at 1-, 3-, and 6-months post-procedure.

    Time frame: Baseline, immediately post-procedure, 1 month, 3 months, and 6 months post-procedure.

  2. Pain Relief - Visual Analog Scale (VAS)

    Additionally, pain relief will be assessed by the Visual Analog Scale (VAS), a continuous scale ranging from 0 to 100 mm, where 0 represents "no pain" and 100 represents "worst possible pain." Pain levels will be recorded at the same time points: baseline, immediately post-procedure, and at 1-, 3-, and 6-months post-procedure.

    Time frame: Baseline, immediately post-procedure, 1 month, 3 months, and 6 months post-procedure.

Secondary outcomes

  1. Medication Consumption

    Changes in medication consumption will be assessed using the Medication Quantification Scale III (MQS III) at 6 months post-procedure. This measure will evaluate the impact of the interventions on the need for medications to manage trigeminal neuralgia.

    Time frame: 6 months post-procedure

  2. Procedure-related Adverse Events

    Adverse events related to the interventions will be systematically recorded to evaluate the safety profile of CT-guided versus fluoroscopy-guided trigeminal ganglion radiofrequency thermocoagulation (TG-RFT). Adverse events will be monitored and recorded immediately post-procedure and during follow-up visits at 1, 3, and 6 months.

    Time frame: Immediately post-procedure, 1 month, 3 months, and 6 months post-procedure

07

Study locations

1 site
  • Zagazig University, Faculty of Medicine
    Zagazig, Sharqia Province 44519, Egypt
08

References and documents

Individual participant data

Plan to share: No — At this time, there is no plan to share individual participant data (IPD) with other researchers. This decision is based on considerations related to patient confidentiality, data privacy concerns, and the absence of a current infrastructure for secure data sharing. The primary results of the study will be published in peer-reviewed journals and presented at scientific conferences, ensuring that the findings are accessible to the broader research community.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in May 2025, 6 months.

Of 33 non-industry interventional studies with no phase under Trigeminal Neuralgia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's 6 months is below that.

Counting every sponsor, half of 33 studies reached it within 27 months; a quarter within 11 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2024
First posted
Oct 1, 2024
StartActual
Nov 10, 2024
Primary completionActual
May 10, 2025
CompletionActual
Oct 10, 2025
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06620172
Lead sponsor
Zagazig University
Responsible party
Ahmed Awad Bessar (Assistant Professor of Diagnostic and Interventional Radiology, Zagazig University) — Principal investigator
First posted
Oct 1, 2024
Start date
Nov 10, 2024
Primary completion
May 10, 2025
Completion
Oct 10, 2025
Last update
Sep 22, 2026

Study contacts

Ahmed A Bessar, MD, PhD
principal investigator · Assistant Professor of Diagnostic and Interventional Radiology, Zagazig Uni.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion